Related Experiment Video

Updated: Sep 28, 2026

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

Low molecular weight heparins in the treatment of unstable angina

W Ageno1, A G G Turpie

  • 1McMaster University, Hamilton, Canada.

Minerva Cardioangiologica
|December 11, 2002
PubMed

Insights

Low molecular weight heparins offer improved efficacy and safety over unfractionated heparin for acute coronary syndromes. Clinical trials show these agents are effective alternatives, but direct comparisons are needed to determine superiority.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Unstable angina and acute coronary syndromes stem from atherosclerotic plaque disruption and thrombus formation.
  • Antithrombotic therapy, particularly aspirin and unfractionated heparin, is crucial for preventing myocardial infarction.

Purpose of the Study:

  • To evaluate the efficacy and safety of low molecular weight heparins (LMWHs) compared to unfractionated heparin in managing unstable angina and non-Q-wave myocardial infarction.
  • To highlight the practical advantages of LMWHs in clinical settings.

Main Methods:

  • Review of clinical trials involving three LMWHs: nadroparin, dalteparin, and enoxaparin.
  • Comparison of LMWHs with unfractionated heparin in terms of efficacy, safety, and pharmacokinetic/pharmacodynamic properties.

Main Results:

  • LMWHs demonstrated comparable safety and efficacy to unfractionated heparin.
  • LMWHs offer significant practical benefits, including subcutaneous administration and fixed dosing without monitoring.
  • Published trials suggest LMWHs are effective alternatives for acute coronary syndrome management.

Conclusions:

  • Low molecular weight heparins are recommended as alternatives to unfractionated heparin in the acute management of acute coronary syndromes.
  • Apparent differences in outcomes between LMWH agents necessitate direct comparative studies to establish superiority.

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...